Clinical Trial

Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation

Name: Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation — clinical trial record (NCT07566585)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The goal of this clinical trial is to test BSB-2002 which is a new type of cellular therapy to treat blood cancer (AML). It will evaluate the safety of BSB-2002 and also determine whether it works to prevent relapse of your cancer.

Trial Details

NCT Number	NCT07566585
Lead Sponsor	BlueSphere Bio, Inc
Conditions	AML - Acute Myeloid Leukemia, AML With Mutated NPM1, AML, Adult Recurrent
Enrollment	19 participants
Start Date	2026-04-21
Primary Completion	2027-08 (estimated)
Study Completion	2027-09 (estimated)
Updated on ClinicalTrials.gov	2026-05-05